Accessibility Menu
Parabilis Medicines logo

Parabilis Medicines(NASDAQ) PBLS

Market Cap$3.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-1%
5 YearN/A
1 YearN/A
1 Month+10%
$31.69
+1.31%
+0.41Today
Parabilis Medicines last closing stock price
MetricPriceDate
Last closeUSD 31.822026-07-27
Parabilis Medicines stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+16.51%USD 27.312026-07-20
1 month+10.49%USD 28.802026-06-26
Since inception-1.01%USD 31.602026-06-10

Parabilis Medicines Financials at a Glance

Market Cap

$3.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$83.64

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-5.48 (Low)

Price

$31.69

Volume

222,286.894

Open

$31.33

Previous Close

$31.82

Daily Range

$30.23 - $31.97

52-Week Range

$20.00 - $34.47

Estimated Earnings Date

Sep 2, 2026

PBLS News

A young scientist recording her findings on a tablet

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

Alex CarchidiJun 27, 2026
Insider.png

Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?

Brendan CoffeyJun 20, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Parabilis Medicines

Parabilis Medicines, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing innovative therapies targeting cancer-causing proteins. The company specializes in cell-penetrating miniproteins (CPMPs) designed to neutralize these proteins within cancer cells, offering potential breakthroughs in cancer treatment.

Products and Services
  • Development of cell-penetrating miniproteins for cancer therapy
  • Targeted treatments aimed at specific cancer-causing proteins
  • Innovative research in biotechnology and drug development
Growth Outlook
  • Strong pipeline of CPMPs in various stages of development
  • Increasing demand for targeted cancer therapies in the healthcare market
  • Strategic partnerships expected to enhance research capabilities
Financial Highlights
  • Market capitalization of approximately $100 million
  • Stock price range between $24.51 and $34.47 over the past year
  • Average trading volume of over 1 million shares
Parabilis Medicines, Inc. is positioned in the biotechnology sector, with a focus on innovative cancer therapies. The company was founded in 2015 and is headquartered in Cambridge, MA. With a dedicated team of 145 employees, Parabilis is committed to advancing its research and development efforts. The recent stock performance indicates a stable interest in the company's potential, with a market cap of around $100 million. The stock has shown resilience, trading within a range that reflects investor confidence. The growth outlook is bolstered by a strong pipeline and increasing market demand for targeted therapies, making Parabilis an intriguing option for those interested in the biotechnology field.
AI Generated • Jul 13, 2026

Industry

Biotechnology

Sector

Health Care

Employees

176

CEO

Mathai Mammen, MD, PhD

Website

parabilismed.com

Headquarters

Cambridge, MA 02140, US

PBLS Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$3.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

118.15M

Volume

222.29K

Avg. Volume

881.49K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Parabilis Medicines Performance Analysis

Parabilis Medicines annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Parabilis Medicines annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -1.37N/A
20252025-12-31USD -1.5815.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$0.61

N/A

Gross Margin

N/A

N/A

Market Cap

$3.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

176

N/A

Net Income

-$45.32

N/A

EBITDA

-$46.85

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$382.19

N/A

Total Debt

$53.15

N/A

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$35.71

N/A

Short Term Debt

$17.43

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$49.57

N/A

Operating Cash Flow

-$49.20

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,396.49-0.00%
^DJIDJI
$52,083.00+0.00%
^IXICNASDAQ
$24,847.16-0.01%
BTCBitcoin
$64,796.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About PBLS

What is the current price of Parabilis Medicines?

Parabilis Medicines is trading at $31.82 per share.

What is the 52-week range for Parabilis Medicines?

Over the past 52 weeks, Parabilis Medicines has traded between $20.00 and $34.47.

How much debt does Parabilis Medicines have?

As of the most recent reporting period, Parabilis Medicines reported total debt of $53.15M.

How much cash does Parabilis Medicines have on hand?

Parabilis Medicines reported $329.04M in cash and cash equivalents in its most recent financial results.

What is Parabilis Medicines’s dividend yield?

Parabilis Medicines does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services